Índice Bovespa

US Dollar vs BRL

Negocie de forma mais inteligente, não mais difícil: Libere seu potencial com nosso conjunto de ferramentas e discussões ao vivo.

Cadastre-se

JNJ Johnson and Johnson

154,29

-1,49 (-0,96%)

26 Nov 2024 - Fechado

Atrasado em 15 minutos

Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities

null

Johnson and Johnson (NYSE:JNJ)
Gráfico Histórico do Ativo
De Out 2024 até Nov 2024

Click aqui para mais gráficos Johnson and Johnson.

Johnson and Johnson (NYSE:JNJ)
Gráfico Histórico do Ativo
De Nov 2023 até Nov 2024

Click aqui para mais gráficos Johnson and Johnson.

Notícias Johnson and Johnson

Johnson & Johnson seeks U.S. FDA approval for subcutaneous induction regimen of TREMFYA® (guselkumab) in ulcerative colitis, a first for an IL-23 inhibitor
Sexta, 22 de Novembro de 2024 (5 dias atrás) • PR Newswire (US)

Health Canada Authorizes CARVYKTI® (ciltacabtagene autoleucel) for Patients with Relapsed or Refractory Multiple Myeloma Who Have Received One to Three Prior Lines of Therapy
Quinta, 21 de Novembro de 2024 (5 dias atrás) • PR Newswire (Canada)

Johnson & Johnson to showcase strength of its broad hematology portfolio and pipeline at the 2024 American Society of Hematology Annual Meeting
Terça, 19 de Novembro de 2024 (1 semana atrás) • PR Newswire (US)

Icotrokinra delivered an industry-leading combination of significant skin clearance with demonstrated tolerability in a once daily pill in Phase 3 topline results
Segunda, 18 de Novembro de 2024 (1 semana atrás) • PR Newswire (US)

Nipocalimab demonstrates significant clinical improvement in disease activity and IgG reduction in Phase 2 Sjögren's disease study
Quinta, 14 de Novembro de 2024 (2 semanas atrás) • PR Newswire (US)

Form 13F-HR - Quarterly report filed by institutional managers, Holdings
Quarta, 13 de Novembro de 2024 (2 semanas atrás) • Edgar (US Regulatory)

Nipocalimab is the first and only investigational therapy granted U.S. FDA Breakthrough Therapy Designation for the treatment of adults living with moderate-to-severe Sjögren's disease
Segunda, 11 de Novembro de 2024 (2 semanas atrás) • PR Newswire (US)

Johnson & Johnson submits applications in the U.S. and EU seeking approval of DARZALEX FASPRO® / DARZALEX® as subcutaneous monotherapy for high-risk smoldering multiple myeloma
Sexta, 8 de Novembro de 2024 (3 semanas atrás) • PR Newswire (US)

Johnson & Johnson advances leadership in rheumatic disease innovation with 43 abstracts at ACR 2024
Quinta, 7 de Novembro de 2024 (3 semanas atrás) • PR Newswire (US)

Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities
Quarta, 6 de Novembro de 2024 (3 semanas atrás) • Edgar (US Regulatory)

Empower 2024 Delivers Groundbreaking Insights and Innovation to Achieve Data-Driven Healthcare
Segunda, 4 de Novembro de 2024 (3 semanas atrás) • GlobeNewswire Inc.

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
Sexta, 1 de Novembro de 2024 (4 semanas atrás) • Edgar (US Regulatory)

Mais Notícias de Johnson and Johnson

FG New America Acquisition

Platinum Studios (CE)

Delayed Upgrade Clock

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições